EUCTR2014-004177-16-Outside-EU/EEA进行中（未招募）不适用
A Phase 4, Randomized, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 321
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Aged 3 to 6 months (defined as the first day the subject is 3 months of age to the last day the subject is 6 months of age) at time of enrollment.
- •2.Available for entire study period and whose parent/legal guardian can be reached by telephone.
- •3.Healthy infant as determined by medical history, physical examination, and judgment of the investigator.
- •4.Subject’s parent/legal guardian must be willing and able to comply with scheduled visits, treatment plan and other study procedures.
- •5.Evidence of a personally signed and dated informed consent document indicating that the subject’s parent/legal guardian has been informed of all pertinent aspects of the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 321
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, or pertussis vaccines.
- •2.A previous anaphylactic reaction to any vaccine or vaccine-related component.
- •3.Contraindication to vaccination with a pneumococcal conjugate, diphtheria, tetanus, or pertussis vaccines.
- •4.Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.
- •5.Known or suspected immune deficiency or suppression.
- •6.History of culture-proven invasive disease caused by S pneumoniae (example [e.g.], meningitis, bacteremia, osteomyelitis, arthritis).
- •7.Major known congenital malformation or serious chronic disorder (eg, Down syndrome, diabetes, sickle cell anemia).
- •8.Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb’s palsy.
- •9.Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis) within the past 3 months.
- •10.Participation in other studies before the current study begins and/or during study participation.
- •11.Subjects who are direct descendants (child, grandchild) of investigational site staff members or subjects who are direct descendants (child, grandchild) of Pfizer employees directly involved in the conduct of the trial.
- •12.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or test drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
1 期
A clinical research study to see how six medications that are approved for the treatment of HIV-1 infection affect the kidneys. The six approved medications are Stribild, Truvada, Atripla, Reyataz, Norvir, and Kivexa. Both the patient and the investigator will know which medication the patient is receiving. This is a randomised (by chance, like the flip of a coin) studyHuman Immunodeficiency Virus, Type 1 (HIV-1) InfectionMedDRA version: 17.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-002095-93-ESGilead Sciences, Inc.72
进行中（未招募）
1 期
A clinical research study to see how six medications that are approved for the treatment of HIV-1 infection affect the kidneys. The six approved medications are Stribild, Truvada, Atripla, Reyataz, Norvir, and Kivexa. Both the patient and the investigator will know which medication the patient is receiving. This is a randomised (by chance, like the flip of a coin) studyEUCTR2014-002095-93-GBGilead Sciences, Inc.100
进行中（未招募）
不适用
A clinical research study to see how six medications that are approved for the treatment of HIV-1 infection affect the kidneys. The six approved medications are Stribild, Truvada, Atripla, Reyataz, Norvir, and Kivexa. Both the patient and the investigator will know which medication the patient is receiving. This is a randomised (by chance, like the flip of a coin) studyHuman Immunodeficiency Virus, Type 1 (HIV-1) InfectionMedDRA version: 17.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-002095-93-BEGilead Sciences, Inc.100
进行中（未招募）
1 期
A clinical research study to see how six medications that are approved for the treatment of HIV-1 infection affect the kidneys. The six approved medications are Stribild, Truvada, Atripla, Reyataz, Norvir, and Kivexa. Both the patient and the investigator will know which medication the patient is receiving. This is a randomised (by chance, like the flip of a coin) studyHuman Immunodeficiency Virus, Type 1 (HIV-1) InfectionMedDRA version: 17.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-002095-93-IEGilead Sciences, Inc.115
尚未招募
4 期
A Phase 4, Open Label, Randomized Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Arterolane Maleate–Piperaquine Phosphate Tablets in Comparison to Artemether–Lumefantrine Tablets for the Treatment of uncomplicated falciparum Malaria in Adolescent and Adult Patients in NigeriaMalariaPACTR202305878745601RANBAXY NIGERIA LTD. a SUN PHARMA company250